Vaccines for preventing herpes zoster in older adults.
暂无分享,去创建一个
M. Torloni | Maria R Torloni | Anna M Z Gagliardi | Brenda N G Andriolo | Bernardo G O Soares | Anna Gagliardi | Bernardo G O Soares
[1] R. Whitley,et al. Clinical practice. Herpes zoster. , 2002, The New England journal of medicine.
[2] A. Hall,et al. What does epidemiology tell us about risk factors for herpes zoster? , 2004, The Lancet. Infectious diseases.
[3] M. Irwin,et al. Augmenting Immune Responses to Varicella Zoster Virus in Older Adults: A Randomized, Controlled Trial of Tai Chi , 2007, Journal of the American Geriatrics Society.
[4] Nichole E Carlson,et al. Duration of humoral immunity to common viral and vaccine antigens. , 2007, The New England journal of medicine.
[5] D. Partridge,et al. The treatment of varicella-zoster virus infection and its complications , 2009, Expert opinion on pharmacotherapy.
[6] S. Tyring,et al. Family history as a risk factor for herpes zoster: a case-control study. , 2008, Archives of dermatology.
[7] Gordon Guyatt,et al. An emerging consensus on grading recommendations? , 2006, ACP journal club.
[8] Huseyin Naci,et al. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers , 2013, BMC Medicine.
[9] E. Ledent,et al. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. , 2012, The Journal of infectious diseases.
[10] Lidia Oostvogels,et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. , 2016, The New England journal of medicine.
[11] L. Smeeth,et al. Herpes Zoster Vaccine Effectiveness against Incident Herpes Zoster and Post-herpetic Neuralgia in an Older US Population: A Cohort Study , 2013, PLoS medicine.
[12] L. Cámpora,et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study. , 2018, Vaccine.
[13] G. Icardi,et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: A randomized study of a single dose vs. two different two-dose schedules , 2013, Human vaccines & immunotherapeutics.
[14] Y. Shoenfeld,et al. The new H1N1 and HPV vaccines and old fears , 2010, Current opinion in rheumatology.
[15] J. Hornberger,et al. Cost-Effectiveness of a Vaccine To Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults , 2006, Annals of Internal Medicine.
[16] Jianjun Li,et al. Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age. , 2007, Vaccine.
[17] A. Rice,et al. Postherpetic Neuralgia , 2014 .
[18] M. Levin,et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. , 2018, Vaccine.
[19] R. K. Evans,et al. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. , 2016, The Lancet. Infectious diseases.
[20] F. Marra,et al. Increasing incidence associated with herpes zoster infection in British Columbia, Canada , 2016, BMC Infectious Diseases.
[21] K. Schmader,et al. Treatment and prevention of postherpetic neuralgia. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] J. Sadoff,et al. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. , 2007, Vaccine.
[23] C. Chan,et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. , 2000, Vaccine.
[24] P. Peduzzi,et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. , 2005, The New England journal of medicine.
[25] P. Moore,et al. VZV: pathogenesis and the disease consequences of primary infection -- Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis , 2007 .
[26] M. Levin,et al. Varicella zoster virus-specific cytotoxicity following secondary immunization with live or killed vaccine. , 1996, Viral immunology.
[27] Y. Shoenfeld,et al. Transverse myelitis and vaccines: a multi-analysis , 2009, Lupus.
[28] Y. Shoenfeld,et al. The autoimmune/inflammatory syndrome induced by adjuvants (ASIA)/Shoenfeld’s syndrome: descriptive analysis of 300 patients from the international ASIA syndrome registry , 2018, Clinical Rheumatology.
[29] R. Cervera,et al. Catastrophic antiphospholipid (Asherson's) syndrome. , 2006, British journal of hospital medicine.
[30] Jianjun Li,et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. , 2012, Vaccine.
[31] Shinn-Jang Hwang,et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. , 2015, The New England journal of medicine.
[32] M. Irwin,et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. , 2008, The Journal of infectious diseases.
[33] G. Guyatt,et al. Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.
[34] K. Kawai,et al. Systematic review of incidence and complications of herpes zoster: towards a global perspective , 2014, BMJ Open.
[35] K. Reisinger,et al. Safety and tolerability of zoster vaccine in adults ≥60 years old , 2011, Human vaccines.
[36] AL Gruver,et al. Immunosenescence of ageing , 2007, The Journal of pathology.
[37] T. Ohkubo,et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double‐blind, placebo‐controlled trial , 2016, Diabetic medicine : a journal of the British Diabetic Association.
[38] C. Dantec,et al. Epigenomic revolution in autoimmune diseases , 2015 .
[39] T. Heineman,et al. Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly , 2016, Human vaccines & immunotherapeutics.
[40] K. Schmader,et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] C. Kensil,et al. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. , 1991, Journal of immunology.
[42] T. Nurmikko,et al. Polymorphism of the IL-10 Gene is Associated with Susceptibility to Herpes Zoster , 2002, Scandinavian journal of infectious diseases.
[43] G. Keating,et al. Zoster Vaccine (Zostavax®) , 2010, Drugs & aging.
[44] D J Newell,et al. Intention-to-treat analysis: implications for quantitative and qualitative research. , 1992, International journal of epidemiology.
[45] D G Altman,et al. Indirect comparisons of competing interventions. , 2005, Health technology assessment.
[46] G. Guyatt,et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. , 2006, Chest.
[47] P. van Damme,et al. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su. , 2017, Vaccine.
[48] Hope-Simpson Re. THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS. , 1965 .
[49] E. Trannoy,et al. A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. , 1998, The Journal of infectious diseases.
[50] T. Schwarz,et al. Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older , 2017, The Journal of infectious diseases.
[51] A. Leplège,et al. Herpes Zoster Pain, Postherpetic Neuralgia, and Quality of Life in the Elderly , 2011, Pain practice : the official journal of World Institute of Pain.
[52] E. Trannoy,et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. , 2000, Vaccine.
[53] B. Yawn,et al. Increasing Incidence of Herpes Zoster Over a 60-year Period From a Population-based Study. , 2016, Clinical Infectious Diseases.
[54] M. Braun,et al. Postlicensure safety surveillance for varicella vaccine. , 2000, JAMA.
[55] K. Schmader,et al. Effect of a Zoster Vaccine on Herpes Zoster–Related Interference with Functional Status and Health‐Related Quality‐of‐Life Measures in Older Adults , 2010, Journal of the American Geriatrics Society.
[56] J. Y. Huh,et al. Disease burden of herpes zoster in Korea. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[57] W. Chung,et al. The Incidence and Risk of Herpes Zoster in Patients With Sleep Disorders , 2016, Medicine.
[58] J. García de Lomas,et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial. , 2015, Vaccine.
[59] K. Schmader,et al. The Impact of Acute Herpes Zoster Pain and Discomfort on Functional Status and Quality of Life in Older Adults , 2007, The Clinical journal of pain.
[60] Y. Yew,et al. Severe Autoimmune Adverse Events Post Herpes Zoster Vaccine: A Case-Control Study of Adverse Events in a National Database. , 2015, Journal of drugs in dermatology : JDD.
[61] R. Gupta,et al. Adjuvants for human vaccines--current status, problems and future prospects. , 1995, Vaccine.
[62] A. Arvin. Aging, immunity, and the varicella-zoster virus. , 2005, The New England journal of medicine.
[63] S. Sutradhar,et al. Comparison of the Levels of Immunogenicity and Safety of Zostavax in Adults 50 to 59 Years Old and in Adults 60 Years Old or Older , 2009, Clinical and Vaccine Immunology.
[64] Y. Shoenfeld,et al. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. , 2013, Journal of autoimmunity.
[65] B. Weaver. The Burden of Herpes Zoster and Postherpetic Neuralgia in the United States , 2007, The Journal of the American Osteopathic Association.
[66] E. Riedmann,et al. Letter from the Editor , 2013, Human vaccines & immunotherapeutics.
[67] M. Levin,et al. Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. , 2007, Vaccine.
[68] P. Chomez,et al. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives , 2007, Expert review of vaccines.
[69] K. Schmader,et al. Safety of Herpes Zoster Vaccine in the Shingles Prevention Study , 2010, Annals of Internal Medicine.
[70] K. Schmader,et al. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. , 2008, The Journal of infectious diseases.
[71] David P. Martin,et al. Herpes zoster (shingles) and postherpetic neuralgia. , 2009, Mayo Clinic proceedings.
[72] E. Ledent,et al. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age. , 2013, The Journal of infectious diseases.
[73] K. Schmader,et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster , 2009, PAIN®.
[74] I. D. de Bruijn,et al. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. , 2007, Vaccine.
[75] Ivan S. F. Chan,et al. A Double-Blind, Randomized, Controlled, Multicenter Safety and Immunogenicity Study of a Refrigerator-Stable Formulation of Zostavax , 2007, Clinical and Vaccine Immunology.
[76] D. Rimland,et al. Increasing incidence of herpes zoster among Veterans. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[77] Joanne Benhamu,et al. Revisiting adverse reactions to vaccines: A critical appraisal of Autoimmune Syndrome Induced by Adjuvants (ASIA). , 2015, Journal of autoimmunity.
[78] M. Levin,et al. Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults. , 1994, Viral immunology.
[79] D. Persing,et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents , 2004, Expert opinion on biological therapy.
[80] Ivan S F Chan,et al. Safety and Immunogenicity Profile of the Concomitant Administration of ZOSTAVAX and Inactivated Influenza Vaccine in Adults Aged 50 and Older , 2007, Journal of the American Geriatrics Society.
[81] K. Schmader,et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. , 2009, The Journal of infectious diseases.
[82] A. Arvin,et al. Varicella-zoster virus , 1996, Clinical microbiology reviews.
[83] M. Levin,et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. , 2010, Vaccine.
[84] C. Macintyre,et al. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old , 2010, Human vaccines.
[85] C. Grose,et al. Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. , 1986, Journal of immunology.
[86] Jae-We Cho,et al. Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster in Korea. , 2007, Journal of dermatological science.
[87] Tzeng-Ji Chen,et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. , 2009, Acta dermato-venereologica.
[88] V. Abraira,et al. [Investigation methods in clinical cardiology. IV. Clinical measurements in cardiology: validity and errors of measurements]. , 1997, Revista espanola de cardiologia.
[89] R. Cohrs,et al. Neurologic complications of the reactivation of varicella-zoster virus. , 2000, The New England journal of medicine.
[90] A. Sabato,et al. No evidence of family history as a risk factor for herpes zoster in patients with post‐herpetic neuralgia , 2010, Journal of medical virology.
[91] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[92] T. Spector,et al. Causal Relationship between Obesity and Vitamin D Status: Bi-Directional Mendelian Randomization Analysis of Multiple Cohorts , 2013, PLoS medicine.
[93] K. Schmader,et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. , 2004, The journal of pain : official journal of the American Pain Society.
[94] Manfred S. Green,et al. Diabetes as a Risk Factor for Herpes Zoster Infection: Results of a Population-Based Study in Israel , 2008, Infection.
[95] Kenneth J. Smith,et al. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[96] D. Machin,et al. Intention to treat--who should use ITT? , 1993, British Journal of Cancer.
[97] R. Dworkin,et al. Acute pain in herpes zoster and its impact on health-related quality of life. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[98] J. B. Cabello,et al. Las mediciones clínicas en cardiología: validez y errores de medición , 1997 .
[99] R. Epstein,et al. Herpes zoster and quality of life , 1995, Neurology.
[100] M. Kicinski. Publication Bias in Recent Meta-Analyses , 2013, PloS one.
[101] Lee Bw. Review of varicella zoster seroepidemiology in India and South‐east Asia , 1998 .
[102] E. Ledent,et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. , 2014, Vaccine.
[103] R. Reichman,et al. Herpes Zoster-Varicella Infections in Immunosuppressed Patients , 1978 .